Qiagen adjusts portfolio in Europe, shares track diagnostics peers

By Daniel Hoffmann, Chart & Technicals desk. Reviewed prior to publication on 2026-06-25, 20:30.

Qiagen N.V. (NL0012169213) is restructuring parts of its German presence, with Qiagen GmbH in Hilden reported in liquidation in the latest company register filing. The diagnostics group continues to trade on the Frankfurt exchange, where its shares remain part of Germany's broader life-sciences universe.

Subsidiary in liquidation in Hilden

The German commercial register for Hilden lists Qiagen GmbH as in liquidation, marking a formal step in winding down this specific entity within the Qiagen corporate structure. The filing notes a liquidation representative and confirms the legal status change in the register of companies in North Rhine-Westphalia.

Qiagen uses multiple legal entities worldwide to manage manufacturing, R&D and distribution, and the liquidation of one subsidiary does not alter the continued operation of Qiagen N.V. as the listed parent. The parent company remains headquartered in Venlo in the Netherlands and maintains significant operations in Hilden, where Qiagen has long run production and development facilities for molecular testing consumables.

Diagnostics footprint and listed parent

Qiagen N.V. is a global provider of sample and assay technologies used in molecular diagnostics, applied testing and academic research, and its shares are listed in Frankfurt as well as in New York via an NYSE listing. The group reports more than 500,000 customers worldwide across clinical laboratories, pharmaceutical companies and research institutions.

In recent years, Qiagen has focused on consolidating production sites and optimizing its portfolio of entities to align with demand for automated molecular testing platforms, including in infectious disease, oncology and human genetics. The ongoing adjustments to its legal entity structure in Germany sit alongside regular investments in new instruments and consumables tailored to high-throughput sequencing and PCR workflows.

How Qiagen generates revenue

Qiagen generates most of its revenue by selling sample preparation kits, molecular diagnostics assays and automation instruments to clinical laboratories and research customers. Flagship platforms include the QIAstat-Dx syndromic testing system and QIAsymphony for automated sample processing.

Where the stock trades today

Qiagen N.V. shares most recently traded around 38.50 euros on the Frankfurt exchange, with the price as of 2026-06-25, 18:00, reflecting a stable performance in the European diagnostics peer group.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.